Supporting ultra‑low‑volume orphan drug launches with complex secondary packaging

Discover how Ensera provided an orphan drug customer with flexible secondary packaging, labeling, and kitting for highly specialized injectable products in very low volumes.

The challenge

When a specialist biopharma company approached Ensera, they already had their established upstream fill-finish strategies in place. What they needed was a trusted specialist to manage the late-stage complexity of commercial supply at the very low volumes typical of orphan drug programs.

Across multiple orphan drug products, the company faced a common set of challenges:

Ultra‑small batch sizes, in some cases only hundreds of units per batch and annual volumes in the low tens of thousands
High SKU proliferation, driven by multiple strengths, smart device labels, and country‑specific artwork
Complex kit assemblies, combining injectable drug product with multiple ancillary components and instructions for use
Stringent labeling requirements, including precise label placement, variable data control, and vision‑based verification
High financial risk, where every unit of product represents significant value and a high cost if mishandled

Many large contract packaging organizations are either unwilling or less well-suited to handle this combination of low volume, high variability, and complexity in a commercially viable way.

The solution

Ensera is different. With our modular and flexible facility design, we were set up to be able to:

Confidently support low‑volume commercial supply without forcing inappropriate automation
Offer flexibility between manual, semi-automated, and configurable processes depending on the product
Manage frequent changeovers and parallel SKUs without compromising quality or compliance
Demonstrate absolute reliability and control when handling high‑value drug product
Act as a long-term partner across multiple orphan drug programs, not just a single launch

The execution

Rather than forcing a one‑size‑fits‑all solution, Ensera configured bespoke line setups for each program, combining:

Manual, semi-automated and automated assembly operations suited to low volumes
Table‑top and inline labeling solutions with integrated vision inspection
Manual kitting and packing processes designed for flexibility and accuracy

Across the different programs, Ensera now supports:

Labeling of injectable primary containers with tight positional tolerances
Assembly of multi‑component injection kits containing drug product and auxiliary items
Blistering and secondary packing with non‑standard formats and materials
Multi‑country artwork management resulting in dozens of SKUs per product

Where appropriate, Ensera leverages existing equipment platforms (including modular assembly and labeling systems) while adapting procedures and workflows to each product’s specific requirements and constraints.

The impact

Through this unique approach, Ensera enabled its orphan drug customer to:

Commercialize highly specialized products at volumes others often don’t accept
Navigate significant SKU and artwork complexity without disrupting supply
Scale supply pragmatically over time, without over‑investing in automation too early
Consolidate secondary packaging activities with a single, reliable European partner across multiple programs

Several products have successfully launched, with additional programs, as well as new orphan drug customers, now progressing through line setup and validation, reinforcing Ensera’s position as a trusted partner for low-volume, high-complexity orphan drug packaging.

For orphan drug sponsors, this flexibility and reliability can be the difference between a feasible launch and a stalled one.

Talk to us about packaging complex, low‑volume drug products.

Get in touch today. We’re ready to help.

Enquire now